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ABSTRACT
Despite significant progress in reducing peripartummother-to-child transmission (MTCT) of human immunodeficiency virus (HIV)
with antiretroviral therapy (ART), continued access toART throughout the breastfeeding period is still a limiting factor, and breast
milk exposure toHIV accounts for up to 44%ofMTCT.As abstinence frombreastfeeding is not recommended, alternativemeans are
needed to preventMTCTofHIV.We have previously shown that oral vaccination at birthwith live attenuatedMycobacterium tuber-
culosis strains expressing simian immunodeficiency virus (SIV) genes safely induces persistent SIV-specific cellular and humoral
immune responses both systemically and at the oral and intestinal mucosa. Here, we tested the ability of oralM. tuberculosis
vaccine strains expressing SIVEnv andGag proteins, followed by systemic heterologous (MVA-SIVEnv/Gag/Pol) boosting, to protect
neonatalmacaques against oral SIV challenge.While vaccination did not protect infantmacaques against oral SIV acquisition, a subset
of immunized animals had significantly lower peak viremiawhich inversely correlatedwith prechallenge SIVEnv-specific salivary and
intestinal IgA responses andhigher-avidity SIVEnv-specific IgG in plasma. These controller animals alsomaintainedCD4T cell pop-
ulations better and showed reduced tissue pathology compared to noncontroller animals.We show that infants vaccinated at birth can
develop vaccine-induced SIV-specific IgA and IgG antibodies and cellular immune responseswithinweeks of life. Our data further
suggest that affinitymaturation of vaccine-induced plasma antibodies and induction ofmucosal IgA responses at potential SIV entry
sites are associatedwith better control of viral replication, thereby likely reducing SIVmorbidity.
IMPORTANCE
Despite significant progress in reducing peripartumMTCT of HIV with ART, continued access to ART throughout the breast-
feeding period is still a limiting factor. Breast milk exposure to HIV accounts for up to 44% ofMTCT. Alternative measures, in
addition to ART, are needed to achieve the goal of an AIDS-free generation. Pediatric HIV vaccines constitute a core component
of such efforts. The results of our pediatric vaccine study highlight the potential importance of vaccine-elicited mucosal Env-
specific IgA responses in combination with high-avidity systemic Env-specific IgG in protection against oral SIV transmission
and control of viral replication in infant macaques. The induction of potent mucosal IgA antibodies by our vaccine is remarkable
considering the age-dependent development of mucosal IgA responses postbirth. A deeper understanding of postnatal immune
development may inform the design of improved vaccine strategies to enhance systemic andmucosal SIV/HIV antibody re-
sponses.
The WHO and UNAIDS have reported that 200,000 infantsworldwide became newly infected with human immunodefi-
ciency virus type 1 (HIV-1) in 2014. Adolescent girls and women
are twice as likely to acquireHIV asmen and represent about 55 to
60% of HIV-infected adults. Despite improved access to antiret-
roviral therapy (ART), especially during the peripartum period,
the rate of mother-to-child-transmission (MTCT) of HIV is esti-
mated at 16% (1). Main obstacles in the prevention of MTCT of
HIV are loss of follow-up for mothers throughout the breast-
feeding period and failure to continually test both mother and
child for HIV infection during this period. Breast milk transmis-
sion of HIV accounts for about half of new pediatric HIV infec-
tions. Thus, alternative measures, in addition to ART, are needed
to achieve the goal of an AIDS-free generation. Pediatric HIV
vaccine development should constitute a core component of such
efforts.
Sub-Saharan Africa carries the greatest burden of the pediatric
HIVepidemic,which is exacerbatedby the limitedresourcesavailable
to prevent new and treat existingHIV infections. Similarly, numbers
of pediatric infections withMycobacterium tuberculosis are highest
in sub-Saharan Africa. Building on the positive attributes and
wide use of the current bacillus Calmette Guérin (BCG) vac-
cine for preventing severe complications of tuberculosis (TB)
in infants, we aimed to develop a pediatric combination vac-
cine, consisting of a recombinant attenuated M. tuberculosis
vaccine strain expressing immunodeficiency virus antigens
that could protect against both HIV and TB infections in hu-
man infants.
crossmark
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We previously reported that the auxotroph M. tuberculosis
strain mc26435, expressing simian immunodeficiency virus (SIV)
Gag, is safe in healthy and SIV-infected neonatal macaques, and
we demonstrated that a peroral (p.o.)M. tuberculosis-SIV prime/
intramuscular (i.m.) modified vaccinia Ankara (MVA)-SIV boost
regimenwas effective for inducing cellular and humoral responses
against SIV andM. tuberculosis antigens in infantmacaques (2, 3).
The oral prime was included to specifically elicit SIV-specific im-
mune responses at potential sites of viral entry in the oro-gastro-
intestinal tract (GI) after oral SIV exposure. The oral mucosa con-
tains lymphoid tissues that are readily accessed by p.o. vaccines.
The lymphatic network of the Waldeyer’s Ring provides a nonin-
vasive portal for oral vaccine uptake and, as part of the systemic
lymphatic network, allows the induction of mucosal and systemic
immune responses. The current studies were designed to test the
efficacy of a p.o. M. tuberculosis-SIV prime/i.m. MVA-SIV boost
regimen for preventing oral SIV acquisition in infant macaques.
To simulate breast milk exposure to HIV in human infants, we
developed a repeated low-dose oral SIV challenge regimen that
permitted determination of the number of exposures required for
SIV infection. Compared to vaccine challenge studies with adult
macaques, both our vaccination regimen and the time to chal-
lengewere accelerated, because the goal of our studies is to identify
a vaccination strategy that will prevent HIV breast milk transmis-
sion early after birth.
So far, with the exception of passive immunization strategies,
only a single pediatric SIV study reported protection against oral
SIV challenge in MVA-SIV- or ALVAC-SIV-vaccinated neonatal
macaques (4), with the caveat that the potential contribution of
genetic host factors, e.g., major histocompatibility complex
(MHC) genotype or SIV restriction factors, to protection could
not be evaluated at that time. As found for most pediatric SIV
vaccines (5–8), vaccination of infant macaques with theM. tuber-
culosis-SIV prime/MVA-SIV boost regimen was not able to pre-
vent oral SIV acquisition in infantmacaques. However, a subset of
vaccinated infants was able to partially control viremia through-
out the study period. Reduced viremiawas associatedwith higher-
avidity SIV Env-specific IgG antibodies in plasma and greater sal-
ivary and intestinal SIV Env-specific IgA responses at the time of
oral SIV challenge initiation. Despite the inability to provide ster-
ilizing protection, and despite the age-restricted development of
IgG and IgA antibodies postnatally, these results suggest that the
induction of potent and persistent antibody responses by early
pediatric vaccination is feasible.
MATERIALS AND METHODS
Animals. Infant rhesus macaques (Macaca mulatta) were enrolled from
the SIV- and type D retrovirus-negative colony at the California National
Primate Research Center (CNPRC; Davis, CA). Animals were housed in
nursery facilities and reared according to theGuide for the Care and Use of
LaboratoryAnimalsused by theAmericanAssociation forAccreditation of
Laboratory Animal Care (9). To enhance social interactions and normal
development, all infants were housed in pairs. All animal protocols were
approved by the UCDavis Institutional Animal Care and Use Committee
prior to study initiation. Trained animal technicians monitored the ani-
mals daily for any clinical symptoms of TB infection. Animals were ran-
domly assigned to groups and were between 3 and 7 days of age at the first
immunization (week 0 in Table 1). All procedures were done following
intramuscular (i.m.) administration of 10 mg ketamine-HCl (Parke-Da-
vis, Morris Plains, NC) per kg of body weight. Complete blood counts
(CBC) were performed on each peripheral blood sample by the CNPRC
Clinical Laboratory.
To assess IgG and IgA antibody development in infant macaques, we
used genetically outbred healthy non-specific-pathogen-free macaques
that were raised in outdoor corrals. Blood and saliva samples were col-
lected without anesthesia during normal monthly health checks.
Vaccines. The construction and immunological characterization of
the recombinant Mycobacteria tuberculosis-SIV strain mc26435 has been
previously described in detail (3). Briefly, strain mc26435, derived from
humanH37RvMycobacterium tuberculosis, had deletions in genes panCD
and leuCD to produce a double auxotroph strain with severe attenuations
for replication. The nonessential secretory gene secA2was also eliminated
to limit immune evasion. In addition, full-length SIVmac239 cassettes,
codon optimized for expression by mycobacteria, were combined to cre-
ate the recombinant mc26435 (Gag) (3) and mc26439 (Env) (U. D. Ran-
ganathan, unpublished data) vaccine strains used in this study. Recombi-
nantMVA SIVmac239 Gag/Pol/Env (MVA-SIV; kindly provided by Bernie
Moss and Patricia Earl, National Cancer Institute) was used to boost SIV-
specific responses. We previously demonstrated that vaccination with
strain mc26435, despite its very low replicative capacity, could safely in-
duce persistent Mycobacterium tuberculosis- and SIV-specific T cell and
antibody responses in neonatal macaques following oral vaccination at
birth (2).
Immunizations. The vaccination regimen is outlined in Table 1. Na-
ive control animals (group A; n 6) received sterile phosphate-buffered
saline (PBS) at birth by the p.o. route and at weeks 3 and 6 by the i.m.
route. Group B (n 8) animals were p.o. primedwith 109 CFU each ofM.
tuberculosis-SIV strainsmc26435 (expressing Gag) andmc26439 (express-
ing Env) at week 0. Group B mice then were i.m. boosted with MVA-SIV
(108 infectious units, divided over 4 injection sites) at weeks 3 and 6 of age.
SIV challenge.Beginning at week 9, all animals were challenged by the
p.o. route once per week with 5 103 50% tissue culture infective doses
(TCID50) of SIVmac251 (stock 6/04 grown in rhesus macaque peripheral
blood mononuclear cells [PBMC]) in a volume of 1 ml until plasma
viremia was confirmed at 3 consecutive time points. Once systemic infec-
tion was confirmed, the first PCR-positive time point was considered
week 1 postinfection. Animals were monitored for a minimum of 9
weeks postinfection; animals with controlled viremia were monitored
longer. All animals were euthanized prior to meeting established cri-
teria for AIDS (10).
SIV RNA testing. Longitudinal plasma samples were used for virolog-
ical analysis by reverse transcription-PCR (RT-PCR) for SIV RNA as de-
scribed previously (11). Note that limits of detection depended on input
plasma volume and ranged from 3 to 65 copies/ml, with a mean of 26 and
median of 30. Samples showing transient low viremia followed by SIV
RNA-negative time points were retested to confirm SIV RT PCR results.
Data are reported as SIV RNA copy equivalents per ml of plasma.
Tissue samples were stabilized in RNAlater (Ambion), rinsed in cat-
ion-free phosphate-buffered saline, and then processed and analyzed for
levels of SIV gag RNA and SIV gag DNA, normalized to diploid genome
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equivalents of DNA based on simultaneous determination of copy num-
bers for a single-copy sequence in the rhesus macaque CCR5 gene, essen-
tially as described previously (12, 13).
SIV sequence analysis. To characterize founder virus envelope vari-
ants, SIV gp160 was amplified using single-genome amplification (SGA),
sequenced, and compared among vaccinated and control animals. TRIzol
reagent (Life Technologies) was used to purify viral RNA from ultracen-
trifuged plasma samples collected 1 to 2 weeks postinfection. RNA was
reverse transcribed using Superscript III (Invitrogen) with oligo(dT)
primers, the resulting cDNA was serially diluted, and the SIV gp160 was
amplified in a nested PCR assay. The first round of PCR utilized forward
primer GAACTCCGAAGAAGGCTAAGGCTAAT and reverse primer
CAGGGCTCAATCTGCCAGCCT with Q5 polymerase (New England
BioLabs) in a 25-l reaction mixture with the following cycling condi-
tions: 98°C for 30 s, followed by 25 cycles of 98°C for 8 s, 70°C for 20 s, and
72°C for 2 min, and a final hold at 72°C for 2 min. Second-round PCR
utilized 1 l of the first-round mixture in a 25-l reaction mixture with
forward primer ATGGGATGTCTTGGGAATCAGCTGCTT and reverse
primer CCCCTTGTGGAAAGTCCCTGC and similar cycling conditions
to yield an amplicon of approximately 3,295 bp that was confirmed by
agarose gel electrophoresis. The dilution of cDNA that produced 30%
positive reactions was used to perform multiple SGA PCRs to yield ap-
proximately 10 envelope amplicons for sequence analysis from each ani-
mal as well as the inoculum stock. SGA envelope amplicons were directly
sequenced using a set of 8 SIV-specific primers that produced overlapping
reads (performed by theUniversity of ChicagoDNASequencing Facility).
Primers includedATGGGATGTCTTGGGAATCAGCTGCTT, CAGTCA
CAGAACAGGCAATAGA, AAGCAAAGCATAACCTGGAGGT, CTTC
ATGCACAAGGATGAT, CACTTGGCATAAAGTAGGCAAAAATG, AC
ACTACTGTACCATGGCCAAATG, CACTGTAATAAATCCCTTCCAG
TCC, and CCCCTTGTGGAAAGTCCCTGC. Geneious v8.1.3 (14) was
used to assemble reads and generate contigs, which were manually
screened and edited for quality. Full-length sequences obtained for each
animal were aligned using theGeneious alignment tool, and overall diver-
sity was assessed. Envelope sequences found in each animal with0.1%
differences were identified as a single founder virus genotype, while se-
quences with0.1% differences were identified as distinct founder virus
genotypes. A representative sequence for each genotypewas used for com-
parisons among animals. The predominant envelope genotype contained
in the SIVmac251 inoculation stock was used for comparisons. Phyloge-
netic comparisons of SGA variants identified in each animal were done
with a Jukes-Cantor genetic distance model and Neighbor-joining trees
with 10,000 bootstrap resampling replicates. Trees were rooted to the
predominant inoculum stock envelope genotype.
Sample collection and processing. Peripheral blood, saliva, and stool
samples were collected prior to all interventions and throughout the study
period at weeks 0, 3, 6, and 9 and then every 2 weeks until necropsy.
Peripheral blood was collected in EDTA, and plasma was separated by
centrifugation and stored in aliquots at80°C for antibody and viremia
measurements. PBMCwere purifiedusing density gradient centrifugation
with lymphocyte separationmedium (MPBiomedicals, SantaAna, CA) as
described previously (2, 5). Mononuclear cells in tissues collected at the
terminal time point were isolated as described previously (2, 5). Salivary
secretions were collected using Weck-Cel sponges (Beaver Visitec, Wal-
tham, MA), immediately snap-frozen, and later eluted as described pre-
viously (2). When possible, 2 to 3 g of fresh stool was added to 5 ml sterile
PBS supplemented with 1/100 protease inhibitor cocktail (Sigma) and
snap-frozen. Fecal extracts were prepared as described previously (2) by
homogenization, removal of debris by centrifugation, 0.45-mfiltration,
TABLE 1 Animal groups
Group
(n)
Immunization (route) at wk:
Animal
no. Sexh
Genotype SIVmac251 challenge
Age at
euthanasia
(wk)0 3 6 MHC class Ia TRIM5b
Protective
scorec
No. of
exposuresd
No. (%) of
founder
virusese
A (6) PBS (p.o.) PBS (i.m.) PBS (i.m.) 42376 F A*01, A*11, B*17,
B*29
TFP/Q 2 1 2 (1.4, 1.0) 21
42380 F A*01, A*11, B*17,
B*29
TFP/CypA 3 9 1 (0.8) 27
42386 F Unknownf TFP/TFP 1 2 1 (0.3) 22
42388 F A*11, B*17, B*29 TFP/Q 1 5 1 (0.6) 25
42409 M A*08 Q/CypA 1 7 2 (0.3, 0.2) 25
42434 M Unknown TFP/TFP 1 1 1 (0.8, 0.3) 21
B (8) mc26435
mc26439 (p.o.)
MVA-SIV
(i.m.)
MVA-SIV
(i.m.)
42899 F A*01, A*11 TFP/CypA 2 1 1 (0.2) 20
42906 F A*11 Q/Q 1 1 1 (0.4) 22
42924g F A*01 TFP/TFP 2 2 1 (0.5) 34
42929 F A*01, B*01 Not tested 0 2 2 (0.6, 0.8) 20
42937 M A*11, B*01, B*08 Q/CypA 1 1 1 (0.4) 21
42944 M Unknown TFP/Q 0 2 2 (0.1, 1.1) 33
42949 M A*11 TFP/TFP 1 1 2 (0.3, 0.4) 21
42958 F Unknown TFP/TFP 1 6 1 (0.2) 33
a The allelesMamu-A*01, -B*08, and -B*17 have been associated with better disease outcome, whereas alleleMamu-B*01 is associated with higher viremia.
b The TRIM5 genotypes TFP/TFP and TFP/Cyp confer resistance to SIV infection, while the genotypes Q/Q and Q/CypA are associated with increased susceptibility to infection.
c Protective class I alleles and resistant TRIM5 alleles were assigned a value of 1. Genotypes associated with increased susceptibility or disease outcome received a score of1. All
other alleles were assigned a score of 0. The protective genotype score represents the sum of all scores for an individual animal (e.g., animal 42376 has MHC of 1 0 1 0 and
TRIM5 of 0, for a score of2).
d The number of exposures necessary to establish systemic infection.
e The number of founder viruses identified by SGA and gp160 sequencing of plasma virus isolated at weeks 1 to 2 postinfection. The numbers in parentheses indicate the percent
difference from the inoculum consensus sequence for each viral clone analyzed.
f Unknown indicates not positive for any of theMamu class I alleles tested (A*01, A*02, A*08, A*11, B*01, B*02, B808, B*04, B*17, and B*26).
g Vaccinated animals with better control of SIV replication are shaded in gray.
h F, female; m, male.
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and concentration to roughly 0.5 ml using a Millipore-Amicon Ultra-4
50K centrifugal filter unit.
Antiviral binding antibodies and avidity.Antibodies and total IgA or
IgG were measured by enzyme-linked immunosorbent assay (ELISA) as
previously described (15). Viral antigens were recombinant SIVmac251
gp140, gp120 (both from Immune Technology, New York, NY), gp70-
V1V2 (kindly provided by David Montefiori, Duke Medical School),
HIV-2 gp36 (Prospec, East Brunswick, NJ), which has 85% homology to
the SIV gp41 ectodomain (16), and SIVmac251 viral lysate (Advanced Bio-
technologies, Columbia, MD), which was used to measure anti-Gag and
anti-Pol antibodies, as it lacks detectable Env antigen at the dilution used.
All assays for IgA were performed using specimens depleted of IgG as
described previously (17). Antigen-specific IgA or IgG antibody concen-
trations measured in secretions were normalized in accordance with the
total IgA or IgG content. The specific activity (nanograms of IgA or IgG
antibody per microgram of total IgA or IgG) in secretions was deemed
significant if it was greater than themean 3 standard deviations (SD) for
negative controls. The avidity of gp140-specific IgG in plasma was mea-
sured using microtiter plates coated with SIV gp140 in an NaSCN dis-
placement ELISA as described previously (18). The avidity index was cal-
culated by dividing the concentration of anti-gp140 IgG measured in 1.5
M NaSCN-treated wells by that in untreated wells on the same plate.
Neutralizing antibodies. Neutralizing activity was measured as de-
scribed previously (19) using heat-inactivated plasma, TZM-bl cells
(AIDS Reagent Program), and a clone of SIVmac251 (clone C) derived in
the laboratory (GenBank accession number KT447167). This clone was
deemed a tier 1 virus based on the finding that clone C neutralizing anti-
body titers in plasma of SIV-infected adult macaques were virtually iden-
tical to those previously measured in assays with an established tier 1
SIVmac251 (20).
ADCVI.Antibody-dependent cellular viral inhibition (ADCVI) as-
says were performed as described previously (21) using 1/100 dilutions
of heat-inactivated week 9 plasma, human PBMC as effector cells, and
SIVmac251-infected CCR5
 CEM-NKr T cells as target cells. The extent of
infection was determined bymeasuring SIV p27 in culture medium using
the p27 ELISA described below. Because a neutralization-resistant
SIVmac251 was used, results of this assay primarily reflected antibody-de-
pendent cytotoxicity (ADCC) and phagocytic activity in plasma.
SIVp27ELISA.An in-house ELISA, developed as described previously
(22), was used to measure p27 concentration in culture medium. Briefly,
plates were coated overnight with 125 ng/ml goat anti-mouse IgG2a
(SouthernBiotech). The following day, plates were washed, blocked, and
treated for 1 h with 1/100 culture medium harvested from the 2F12 anti-
SIV p27 hybridoma (AIDS Reagent Program). The plates were washed,
loaded with samples and a recombinant p27 standard (ImmuneDiagnos-
tics, Woburn, MA), and then stored overnight at 4°C. Plates were then
washed and treated for 1 h at 37°Cwith biotinylated anti-SIV IgG that had
been purified from pooled SIV-positive macaque serum in the laboratory
using protein G Sepharose (GE Healthcare) and subsequently biotinyl-
ated using EZ-link NHS-Sulfo (Pierce). The plates were developed using
1/2,000 neutralite avidin-peroxidase, TMB (both from SouthernBiotech),
and 2N H2SO4 stop solution.
Antibody-dependent phagocytosis (ADP). Phagocytosis assays were
performed as described previously (23), with modifications noted below.
Briefly, 1  109 1-m NeutrAvidin fluorospheres (Invitrogen) were la-
beled with 7 g biotinylated recombinant SIV gp140mac251 (Immune
Technology). After washing, 1 107 beads per well were added to V-bot-
tom plates containing triplicate serial dilutions of heat-inactivated serum.
THP-1 cells (2 104 per well) were then added. After 6 h at 37°C in 5%
CO2, the cells were washed with Ca
2/Mg2-free Dulbecco’s PBS (DPBS)
and incubated for 10 min with 50 l of 0.05% Trypsin-EDTA (Gibco) to
remove beads that nonspecifically adhere to cell surfaces, allowing specific
assessment of internalized beads. The cells were then washed in DPBS,
resuspended in 1%paraformaldehyde, and analyzed for fluorescence. The
phagocytic score was calculated as described previously (23) by multiply-
ing the number of bead-positive cells by their median fluorescent inten-
sity. The average score for naive monkey serum at the same dilution was
subtracted from test samples to obtain the final score.
Histopathology and immunohistochemistry. Formalin-fixed, paraf-
fin-embedded tissues were cut into 5-m serial sections and hematoxylin
and eosin stained to evaluate SIV-induced pathology by a pathologist
blinded with respect to treatment groups. Criteria included, among oth-
ers, tissue structure, hyperplasia, hypertrophy, cellular influx indicative of
inflammation, hemorrhages, pneumonitis, colitis, bronchitis, spirochet-
osis, and evidence of coinfections. A tissue disease score scale was used to
measure disease severity: 0, no indications of SIV-associated pathology; 1,
mild disease,multifocal; 2,mild disease, diffuse; 3,moderate disease,mul-
tifocal; 4, moderate disease, diffuse; 5, severe disease with mild T cell
depletion; 6, severe disease withmassive T cell depletion. Similarly, tissues
were evaluated in a blindedmanner for TB-indicative pathologies and for
the presence of cryptosporidiosis, an indicator of opportunistic infec-
tions.
Intracellular cytokine staining. Flow cytometry was performed as
described previously (2, 3, 5) using peripheral bloodmononuclear cells or
single-cell suspensions prepared from fresh tissues. Cytokine production
following a 6-h incubation with SIVmac239 Gag and Env peptide pools
(Gag, number 6204; Env, number 6883;NIHAIDSReagent Program)was
used to assay SIV-specific T cells. Phorbol myristate acetate (PMA) and
ionomycin (Sigma) stimulation served as a positive control. Background
responses by unstimulated cell suspensionswere subtracted to account for
nonspecific immune responses. Cells were stained for flow cytometry us-
ing standard protocols (2, 3, 5) and included antibodies for CD3 (clone
SP34-2), CD4 (clone L200), CD8 (clone RPA-T8), interleukin-2 (IL-2;
cloneMQ1-17H12), tumor necrosis factor alpha (TNF-; cloneMAb11),
gamma interferon (IFN-	; clone B27) (all from BD Biosciences), and
IL-17 (clone eBio64CAP17; eBioscience) (2, 5). Intracellular staining us-
ing fixation/permeabilization solution and perm/wash (BD Biosciences)
was performed according to the manufacturer’s instructions. Samples
were resuspended in PBS following fixation and acquired within 24 h on
an LSRII instrument. Samples were analyzed in FlowJo (TreeStar, Ash-
land, OR) using the following gating procedure prior to panel-specific
analysis: (i) lymphocyte gate, (ii) forward scatter area versus forward scat-
ter height and side scatter height versus side scatter width to eliminate
doublets, and (iii) fixable live/dead discriminator (Invitrogen) to discard
dead cells and debris. Boolean gating was applied when appropriate.
Animal genotyping. Snap-frozen splenic cell pellets were typed for the
common MHC class I variantsMamu-A*01, -A*02, -A*08, -A*11, -B*01,
-B*03, -B*04, -B*08, and -B*17, chosen for their possible roles in restrict-
ing SIV infection and/or control of viremia. Genotyping was completed
by theMHCGenotyping Service at the University ofMiamiMiller School
of Medicine, and the established methods have been reported previously
(24–29). Genotypes of the animals are reported in Table 1.
TRIM5 genotyping. The TRIM5 genotype of macaques was deter-
mined by sequence analysis of the C-terminal B30.2/SPRY domain of the
TRIM5 gene (Table 1). Briefly, the region was amplified by PCR utilizing
purified genomic DNA and amplification protocols and primers as de-
scribed previously (30). Resulting PCR fragments were cloned using the
TOPO-TA vector system (Invitrogen), and TRIM5 sequences for each
animal were determined from 5 to 7 clones. The genotypes of TRIM5TFP,
TRIM5Q, and TRIM5CypA were identified and animals were classified as
resistant, intermediate, or sensitive as described previously (30–32).
Statistical analysis. Data were analyzed using GraphPad Prism soft-
ware, version 6.0f (GraphPad Software, Inc., La Jolla, CA), and R, version
3.1.2. The numbers of infections per SIV exposure for unvaccinated or
vaccinated animals were used to estimate the risk of infection per expo-
sure, and results were plotted using the Kaplan Meier method and ana-
lyzed by an exact log-rank test (33–35). For comparisons of three or more
groups, the nonparametric Kruskal-Wallis test was performed. The non-
parametric Mann-Whitney exact test was used for comparison of two
groups. Correlations were evaluated using the Spearman rank test. Two-
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tailed statistical tests were conducted and P values of0.05 were consid-
ered statistically significant. No adjustments were made for multiple hy-
pothesis testing.
Nucleotide sequence accession number.The sequence determined in
the course of this work was deposited in GenBank under accession num-
ber KT447167.
RESULTS
Establishment of a repeated low-dose oral SIVmac251 challenge
model. To mimic the repeated and continuous exposure of hu-
man infants to HIV-1 in breast milk in a relevant animal model
while addressing the practical constraints of nonhuman primate
studies, we previously developed a repeated oral SIVmac251 chal-
lengemodel inwhich infantmacaques were bottle fed 3 daily for
5 consecutive days with 104 TCID50 of SIVmac251 in 1 ml of RPMI
(4, 5). This oral SIVmac251 exposure model resulted in an 80%
infection rate within 2 weeks of the first viral exposure (4, 5). A
limitation of thismodel, however, was that the frequent exposures
in rapid succession did not permit quantification of the number of
exposures required for SIV acquisition. For the present studies, we
used a repeated once-weekly low-dose challenge model to more
precisely evaluate vaccine efficacy by measuring (i) protection
against infection (sterilizing immunity) and/or (ii) partial efficacy
by quantifying the number of challenges required for infection
(4). To achieve 100% infection of control animals, our regimen
aimed for 20 to 50% probability of infection per SIV exposure.
We began once-weekly oral SIVmac251 exposures in naive infant
macaques at 9 weeks of age for a maximum of 10 weeks (Table 1,
group A). All group A animals became persistently infected, al-
though the number of exposures leading to SIV infection varied
greatly within the group (Fig. 1A). Two naive animals became
infected following a single exposure and one animal each became
infected after 2, 5, 7, and 9 exposures (Fig. 1A). The animal that
required 7 exposures (number 42409) experienced low transient
viremia at 2 consecutive time points (550 and 380 copies/ml, re-
spectively), but viral RNAwas undetectable 1 week later. A second
plasma aliquot from the negative time point was tested and con-
firmed to be negative for SIV RNA. Based on our definition of
persistent viral infection as three consecutive plasma SIV RNA-
positive time points, this animal was defined as being uninfected
during the period of low transient viremia. Peak viremia (defined
as the highest viral load during the first 3 weeks of detectable
persistent viremia) in nonvaccinated group A animals ranged
from 7.3  106 to 3.4  108 viral RNA copies/ml plasma (mean,
7.7  107; median, 2.4  107), and viral replication was main-
tained at high levels in all animals (Fig. 1A). The estimated prob-
ability of infection per oral SIV exposure in nonvaccinated group
A infant macaques was 0.24. Although this per-exposure risk of
oral SIV infection is higher than the estimated risk of breast milk
HIV transmission in human infants, we deemed the per-exposure
infection rate for this repeated low-dose oral SIVmac251 challenge
FIG 1 Challenge outcome after repeated low-dose oral SIVmac251 exposure. (A and B) Plasma viremia in naive controls (A) and vaccinated animals (B). Starting
at week 9 of age (black arrow), animals were exposed once weekly with 5,000 TCID50 of SIVmac251 by the oral route. Naive animals are shown as open circles,
vaccinated animals with high and uncontrolled viremia (noncontrollers) are represented by black diamonds, and vaccinated animals that could partially control
viremia (controllers) are shown as gray diamonds. The dashed line at 106 copies of SIVRNA/ml plasma indicates the threshold to define partial control of viremia
in the current study, because most of the nonvaccinated animals had higher peak and chronic viremia throughout the study period. (C) Representing the
per-exposure risk of SIV infection in naive control and vaccinated infantmacaques, the Kaplan-Meier survival plot shows the percentage of naive and vaccinated
animals that remain uninfected after each oral SIV exposure. (D) Median acute viremia (horizontal line), defined as area under the curve (AUC) of plasma
viremia fromweeks 1 to 3 post-SIV infection (PI) in controller and noncontroller animals of group B. (E) Analogous to panel D, but showing differences in early
chronic viremia, defined as the AUC of plasma viremia between weeks 6 and 8 post-SIV infection in controller and noncontroller group B animals. Each symbol
represents an individual animal.
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model to be within a relevant range for vaccine efficacy studies
aimed at recapitulating frequent, low-dose breast milk exposure
with balancing efforts to mimic clinical circumstances and the
practical logistics associated with infant macaque studies.
Challenge outcome in vaccinated infant macaques. The cur-
rent study was designed to test the protective efficacy of the p.o.
mc26435 prime/i.m. MVA-SIV boost vaccine regimen, which we
previously showed to be safe and immunogenic (2, 3) against oral
SIVmac251 transmission in infant macaques (Table 1). As in our
prior study (2), animals were orally primed at birth to induce
SIV-specific immune responses proximal to the presumed sites of
virus entry after oral SIV exposure. To enhance the immunoge-
nicity and the potential efficacy of the vaccine regimen, we used a
cocktail of the newly developed M. tuberculosis strain mc26439
expressing SIV Env and the previously described mc26435 strain
as an oral prime at birth (week 0). Infant macaques were then
boosted i.m. with MVA-SIV at 3 and 6 weeks of age (group B).
Naive controls (group A) were age matched and received sterile
PBS at the same time points and by the same routes as vaccinated
animals (Table 1). Beginning at week 9, all infant macaques were
exposed to SIVmac251 using the weekly oral challenge regimen de-
scribed above for the nonvaccinated animals. Our results showed
that this M. tuberculosis-SIV/MVA-SIV regimen was unable to
prevent oral SIV acquisition (Fig. 1B). In fact, 87.5%of vaccinated
animals became infected after only 1 or 2 exposures compared to
50% of naive controls. The per-exposure risk of SIV infection in
vaccinated animalswas 0.5 (Fig. 1C), whichwas 2-fold higher than
that of naive animals. However, due to the small group sizes, the
difference in the per-exposure risk of SIV infection was not statis-
tically significant (P 0.17). Despite acquisition of SIV, the viral
trajectories in the vaccine group showed that 3 of 8 vaccinated
infants exhibited reduced acute viremia (Fig. 1D) and continued
to exhibit reduced viremia during the early chronic phase of in-
fection (Fig. 1E). These 3 animals were subsequently referred to as
“controllers” and were monitored for 6 months to evaluate long-
term challenge outcome. One of the controller animals (number
42958) eventually showed an increase in viremia (after week 21)
(Fig. 1B), whereas the other 2 infant controller animals main-
tained lower viremia than the noncontrollers until the study end.
We deemed it unlikely that MHC genotype and/or TRIM5 ge-
notype influenced oral SIV challenge outcomes in this study,
because there was no consistent genotype that distinguished
controllers from noncontrollers (Table 1). In addition, TRIM5
genotypes have not been associated with resistance to SIVmac239 or
SIVmac251 infection (36).
There was also no difference in the number of founder viruses
identified between group A and B animals or between vaccinated
noncontroller and controller animals. One or two envelope geno-
types were identified in each of the animals (Table 1), and phylo-
genetic comparisons of founder viruses did not identify significant
clustering between naive and vaccinated animals or between vac-
cinated noncontroller and controller animals (Fig. 2). Differences
in founder viruses compared to the predominant inoculum geno-
type ranged from 0.1 to 1.4% and did not differ among groups.
Anamnestic SIV-specific T cell responses may have contrib-
uted to control of viremia. Although vaccine-induced SIV-spe-
cific immune responses were not sufficient to prevent oral SIV
acquisition, we examined the possibility that the immune re-
sponses at the time of oral SIV challenge initiation (week 9) were
associatedwith reduced viremia in the controller animals. At week
9, SIV Gag-specific CD4 and CD8 T cells producing IL-2,
IFN-	, IL-17, and/or TNF- were detectable in all group B ani-
mals except in one controller, animal number 42944 (Fig. 3A).
However, this animal had SIV-specific T cell responses at week 6
(data not shown). We also measured SIV Env-specific T cell re-
sponses, but due to the small blood volumes available from infant
macaques, these responses could not be tested at all time points for
all animals (Fig. 3B). Therefore, we only sought correlations be-
tween SIV Gag-specific T cell responses and acute viremia. Al-
though neither SIVGag-specific CD4 nor CD8T cell responses
of group B animals at the time of oral challenge correlated with
acute peak viremia (Fig. 3C), SIV Gag-specific CD4 T cell re-
sponses at week 2 postinfection inversely correlated with acute
viremia (Fig. 3D). A similar trend was observed for CD8 T cell
responses but did not reach statistical significance. Thus, anam-
nestic SIV Gag-specific T cell responses may have contributed to
lower viremia of group B controller animals.
Vaccine-induced systemic IgG antibody responses. Only 1
vaccinated animal (number 42949) developed SIV Env-specific
plasma IgG antibodies before MVA-SIV boosting, and these were
only at low levels. This was not surprising, because we have previ-
ously found that even 2 immunizations 3 weeks apart with M.
tuberculosis-SIV did not elicit SIV Env-specific IgG, suggesting
that Env expression by mc26439 is insufficient for induction of
these antibodies (data not shown). In all group B animals, plasma
IgG antibodies to gp140 and gp120 were detected after receiving
the first MVA-SIV boost at week 3, and these were further in-
creased by the second MVA-SIV boost on week 6 (Fig. 4A). In
addition, group B animals also developed IgG antibodies to gp36
and to gp70-V1V2 by week 9 (Fig. 4B), but themagnitude of these
responses at the time of challenge did not differ between controller
and noncontroller animals (Fig. 4B). Plasma from vaccinated an-
imals at week 9 was able to neutralize a tier 1 SIVmac251 (Fig. 4C)
and to mediate ADP of gp140-coated fluorescent beads (Fig. 4D).
However, these activities were not associated with control of
viremia and did not differ between controller and noncontroller
animals, and none of the plasma samples had antibodies capable
of mediating ADCVI against a neutralization-resistant SIVmac251
(data not shown). However, at week 9, the avidity of gp140-spe-
cific IgG antibodies was slightly higher, albeit not significantly, in
controller than noncontroller animals (Fig. 4E), and acute peak
viremia, defined as the area under the curve (AUC) for viremia
measured at weeks 1 to 3 postinfection, was inversely correlated
with the avidity index (Fig. 4F). In both controller and noncon-
troller vaccinated animals, much greater avidity indices were re-
corded at necropsy (Fig. 4G), indicating that the quality of Env-
specific IgG antibodies increased throughout the postinfection
period, although statistically avidity indices did not differ between
controller and noncontroller animals. As functional activities of
plasma antibodies also likely improved during this time (but were
not measured), SIV Env-specific IgG may have contributed to
control of viral replication. No correlations were observed be-
tween plasma anti-SIV Gag, Pol IgG levels, and viremia (data not
shown).
Vaccine-induced systemic and mucosal IgA antibody re-
sponses. As found for plasma IgG, SIVgp140 Env-specific plasma
IgA developed in all group B animals after the first MVA-SIV
boost and was increased further by the second boost (Fig. 5A).
Vaccine-induced gp140-specific IgA was also detected in saliva
and in feces at week 9, the time of the first oral SIV exposure
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(Fig. 5B and C). It should be pointed out that 2 of the controller
animals had specific SIVEnv IgA activities of 97.8 and 117.8 ng/g
total IgA in saliva, a magnitudemuch higher than was observed in
previous pediatric SIV vaccine studies (5). Plasma IgA antibodies
to gp140 were not associated with acute viremia (Fig. 5D). How-
ever, both SIV gp140-specific salivary and fecal IgA responses at
week 9 correlated positively with each other and were inversely
correlated with acute viremia (Fig. 5E to G), whereas there was
little or no correlation betweenmucosal and systemic IgA (Fig. 5H
and I), indicating that the vaccine-induced SIV Env IgA antibod-
ies in saliva and intestinewere produced locally. In contrast to IgA,
SIV gp140-specific IgG in fecal samples was undetectable at week
9. IgG antibodies were not measured in saliva due to limited sam-
ple volume. Table 2 summarizes the correlation between vaccine-
induced plasma and mucosal antibody responses at the time of
oral SIV challenge initiation and acute viremia.
After the vaccinated animals were infected with SIV, we ob-
served no differences in salivary gp140-specific IgA responses be-
tween controller and noncontroller animals (Fig. 6A). In contrast,
the fecal IgA responses to gp140 continued to increase in control-
lers and were significantly greater than those of noncontroller an-
imals at week 6 postinfection and the terminal time point (Fig.
6B). However, there was no correlation between gp140-specific
fecal IgA and plasma SIV RNA levels at the time of necropsy (data
not shown).
Total IgAand IgG inplasmaandsalivaduring thefirst yearof
life. The significance of the magnitude of vaccine-induced muco-
sal Env-specific IgA antibodies and their contribution to control
of virus replication, even if observed in only a subset of animals,
becomes apparent when the above-described IgA results are
viewed in the context of normal postnatal antibody development
in infantmacaques. In plasma, transplacentally transferredmater-
nal IgG is present at birth and is lower at 1 month of age (Fig. 7A).
Once infants begin producing their own IgG, total plasma IgG
levels rapidly reach adult levels (Fig. 7A). A similar decline fol-
lowed by an increase in total IgG was also observed in saliva (Fig.
7B). Interestingly, levels of total salivary IgG in 6- to 7-month-
old infants were significantly higher than those in adult ma-
caques. Together, these results suggest that more plasma IgG in
infant than in adult macaques is passively transudated into the
oral cavity.
Consistent with the fact that IgA antibodies cannot cross the
placenta, median plasma total IgA levels (50.2 g/ml) in infant
macaques were more than 2 logs lower than median plasma IgG
levels (12,262 g/ml) in the first month and gradually increased
with age (Fig. 7C).Median plasma IgA levels in 6- to 7-month-old
FIG 2 SIV Env sequence diversity in naive and vaccinated animals. Phylogenetic tree depicting the 19 founder viral variants found in SIV-infected group A and
B animals. The predominant gp160 variant found in the SIVmac251 inoculum (stock 6/04) was used to root the tree. The horizontal bar shows the scale of genetic
distance. Sequence labels from group B vaccinated animals are boxed, and those from vaccinated controller animals are double boxed.
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FIG3 Prechallenge (week 9) SIV-specificT cell responses in groupB vaccinated infantmacaques. (A) SIVGag-specificT cell responses in peripheral bloodCD4
(left) and CD8 T cells (right). Each bar represents the sum of the percentage of single-cytokine-positive CD4 or CD8 T cells for a specific animal.
Cytokine-positive T cells weremeasured by flow-cytometric analysis that includedTNF- (black), IL-17 (striped), IFN-	 (gray), and IL-2 (white). (B) Analogous
data for SIV Env-specific T cell responses. N.T. (not tested) indicates that no cells were available for measuring SIV Env-specific responses in these animals. (C)
Prechallenge (week 9) SIV Gag-specific CD4 (left) and CD8 T cell (right) responses were log transformed and plotted against acute peak viremia, defined as
area under the curve of plasma viremia in weeks 1 to 3 post-SIV infection, to test for a potential correlation. Note that a value of 0.001 was assigned to animal
number 42944, which did not have detectable T cell responses. (D) SIV Gag-specific CD4 (left) and CD8 (right) T cell responses at week 2 post-SIV infection
were tested for their correlation with acute plasma viremia.
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FIG 4 Vaccine-induced SIV Env-specific plasma IgG responses at week 9. (A) Plasma SIV gp140-specific IgG concentrations at weeks 0, 3, 6, and 9 in naive
controls, noncontroller animals, and controller animals. The times of immunization and the vaccine constructs are indicated by arrows. (B) Plasma IgG
concentrations for gp140, gp120, gp36, and gp70-V1V2 in controller and noncontroller animals at week 9, just prior to oral SIV challenge initiation. (C to E)
Week 9 SIVmac251 neutralization titer (50%), ADP score, and avidity index for controller and noncontroller animals, respectively. (F) The correlation between
anti-gp140 plasma IgG avidity at week 9 and acute viremia. (G) The gp140 plasma IgG avidity index for group B controller and noncontroller animals at the time
of euthanasia. Nx, necropsy.
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infants were still roughly 1 log10 g/ml lower than adult plasma
IgA levels (Fig. 7C). Salivary IgA was almost undetectable at birth
and remained low for the first few months, but it reached adult
levels by 6 to 7 months (Fig. 7D). Thus, considering the very low
levels of total IgA being produced in infant macaques in the first 3
months of life, it is encouraging that the SIVM. tuberculosis/MVA
vaccine was able to induce SIV-specificmucosal IgA responses at a
magnitude that was associated with partial control of viremia in a
subset of infant animals.
Clinical outcome and tissue pathology.To test if the effects of
reduced viremia impacted disease morbidity and progression, we
evaluated clinical markers of HIV/SIV progression in the vacci-
nated controller infant macaques. In lymphoid tissues, SIV-in-
duced pathology ranged from mild hyperplasia to severe disease
with massive T cell depletion. Overall, there was a lower median
pathology score in vaccinated than naive control animals, but tis-
sue pathology did not differ between animals that showed partial
control of viremia and noncontrollers (Fig. 8A). Cryptosporidi-
osis, an opportunistic infection, was present in 20% of mock-
vaccinated animals and 100% of noncontrollers in the ileum,
whereas none of the controller animals developed this opportu-
nistic infection. In the colon, 40% of noncontroller compared to
0% of the controller animals showed cryptosporidiosis, but the
nonvaccinated animals also had no signs of cryptosporidiosis (Fig.
8B). To test whether reduced tissue pathology was indeed associ-
ated with better control of virus replication, we measured colon
SIV RNA and DNA levels. The 3 controller animals had signifi-
cantly lower SIV RNA copies per 1 million cell equivalents than
noncontroller animals, whereas median colon RNA levels were
indistinguishable between the noncontroller and naive control
animals (Fig. 8C). SIV DNA levels, however, were only slightly
reduced in the controller animals. A similar pattern of lower SIV
RNA and DNA levels was observed in the submandibular lymph
nodes and in spleen (data not shown).
Over time, vaccinated controller animals showed better pres-
ervation of peripheral blood CD4 T cells than nonvaccinated or
noncontroller animals (Fig. 8D). Controller animals also better
maintained tissue CD4 T cell populations than noncontroller
FIG 5 Vaccine-induced SIV Env-specific IgA responses prior to SIV challenge. (A) SIV gp140-specific plasma IgA levels at weeks 6 and 9 in naive animals,
noncontroller animals, and controller animals. (B and C) gp140-specific IgA activity in saliva and fecal samples of controller and noncontroller animals at week
9. (D to F) Correlation between plasma, salivary, and fecal gp140-specific IgA at week 9 and acute viremia, respectively. (G) Linear positive correlation between
salivary and fecal IgA at week 9. (H and I) Lack of correlation between plasma IgA and saliva IgA (H) or fecal IgA (I).
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animals (Fig. 8E). While the differences in CD4 T cell frequen-
cies were only statistically significant in mesenteric lymph node
(LN), retropharyngeal LN, and tonsil, a similar trend was ob-
served in other tissues (representatively shown for colon and
bronchoalveolar fluid) (Fig. 8E). Even the animal that eventually
lost control of viremia after week 24 (number 42958) benefitted
from preserved CD4 T cell maintenance, which could be further
indicative of reducedmorbidity from partial viremia control early
after infection. We could not detect a targeted loss of memory
and/or effector CD4 T cells, as all memory subset ratios were
maintained (data not shown). The improved outcome in vacci-
nated controller animals with regard to preservation of CD4T cells
and reduced tissue pathology was noteworthy, especially given the
durationofSIV infection in these3animalswas extendedby10weeks
compared to that of the noncontroller animals.
DISCUSSION
The current study tested the efficacy of a recombinant attenuated
M. tuberculosis-SIV vaccine to prevent oral SIV acquisition in in-
fant macaques. To simulate breast milk transmission of HIV in
TABLE 2 Correlations between vaccine-induced antibody responses at week 9 and acute viremia
Parametera
Spearman correlationb
Correlation r value P value
IgG
Plasma anti-SIV Env IgG
gp140 IgG BAb NS 0.2381 0.5821
gp120 IgG BAb NS 0.0476 0.9349
V1V2 IgG BAb NS 0.2143 0.6191
gp36 IgG BAb NS 0.0952 0.8401
Fecal anti-SIV Env IgG
gp140 IgG BAb Not detectable NA NA
Plasma Gag, Pol IgG NS 0.2143 0.6191
Fecal Gag, Pol IgG Not detectable NA NA
IgA
Plasma gp140 IgA BAb NS 0.4286 0.2992
Salivary gp140 IgA BAb Inverse 0.8571 0.0107
Fecal gp140 IgA BAb Inverse 0.9550 0.0028
Plasma Gag, Pol IgA NS 0.4048 0.3268
Fecal Gag, Pol IgA Not detectable NA NA
Function
Plasma gp140 IgG avidity Inverse 0.7381 0.0458
Plasma ADP None 0.0000 
0.9999
Plasma ADCVI 5% (negative) NA NA
Plasma tier 1 neutralization None 0.3995 0.3894
a BAb, binding antibody.
b NS, not significant; NA, not applicable.
FIG 6 Postinfection salivary and fecal IgA antibodies in vaccinated animals. (A) Salivary SIV gp140-specific IgA activities at weeks 4 and 8 and at the time of
euthanasia in controller and noncontroller animals. (B) Fecal gp140-specific IgA activities at weeks 2 and 6 and at the time of euthanasia in controller and
noncontroller animals. The different time points in panels A and B are a result of sample availability. Nx, necropsy.
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human infants, we applied a repeated oral SIVmac251 challenge
model. In unvaccinated animals, the per-exposure risk of oral SIV
infection using this model was 0.24. This per-exposure infection
rate balances the practical logistics of pediatric nonhuman pri-
mate studieswhilemaintaining clinical relevance for efficacy stud-
ies testing vaccines for the prevention of breast milk transmission
of HIV in human infants.
Applying this weekly oral challenge model, our p.o. M. tuber-
culosis-SIVprime/i.m.MVA-SIVboost strategywas unable to pre-
vent oral SIV acquisition. In fact,more than 80%of the vaccinated
animals became infected after only 1 to 2 oral SIV exposures com-
pared to 50% of mock controls, but this difference was not statis-
tically significant. Despite the lack of protection against oral SIV
acquisition, 3 of 8 vaccinated infants were able to partially control
virus replication. In these controller animals, SIV Env-specific
plasma IgG antibody avidity and the magnitude of SIV Env-spe-
cific mucosal IgA responses at the time of challenge inversely cor-
related with acute peak viremia. SIV-specific T cells may have
contributed to control of viremia as well, because acute viremia
inversely correlated with SIV-specific peripheral blood CD4 T
cell responses. These results also emphasize that certain immune
responsesmight be induced by vaccination and contribute to con-
trol of SIV replication after infection, even though at the time of
challenge, these responses are not detected or do not differ be-
tween vaccinated noncontroller and controller infants. In the cur-
rent study, we could not measure SIV-specific T cell responses in
tissues prior to SIV challenge, but it is possible that SIV-specific T
cell responses, including follicular T helper cell responses, con-
FIG 7 Postnatal antibody development in rhesus macaques. The analysis of plasma and salivary antibodies was performed using cross-sectional samples from
infantmacaques (black symbols) between the ages of 0 (birth) to 7months (Mo). Adult antibody levels (open diamonds) are shown for comparison. The number
of animals in each group is listed in parentheses below the relevant age group. Plasma and salivary total IgG levels (A and B) and plasma and salivary IgA levels
(C andD) in infant compared to adult macaques are shown. Each symbol represents an individual animal, with horizontal bars indicating themedian value. The
nonparametric Mann-Whitney test was performed to determine differences between two specific infant age groups and between 6- to 7-month-old infants and
adults. Note that a monomeric serum IgA standard was used to measure the polymeric IgA. Therefore, the total IgA is likely to be underestimated by a
factor of 2.5.
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FIG 8 Clinical assessment of SIV-infected animals. (A) The median disease score, determined by histological analysis, for animals in group A (naive controls)
and group B animals at the time of euthanasia. Controller and noncontroller animals are represented by gray and black symbols, respectively. (B) The percentage
of animals with detectable cryptosporidiosis in the colon and ileum of naive controls and vaccinated animals at the time of euthanasia. (C) SIV RNA (left y axis)
and DNA levels (right y axis) were measured in colon tissue samples by PCR and are reported as copy numbers per 106 cell equivalents. (D) The percentage of
CD4 T cells within the CD3 population at the time of oral SIV challenge initiation (week 9), at weeks 1 to 2 (acute phase) and weeks 7 to 8 (chronic phase), and
at the time of euthanasia in nonvaccinated animals and in controller and noncontroller vaccinated infant macaques.Median values per group are represented by
horizontal bars. (E) Comparative analysis of CD4 T cell frequencies in selected tissues of mock-vaccinated and vaccinated animals at the time of euthanasia.
Differences between animals in 2 different groups were determined using the nonparametric Mann-Whitney test. Mes, mesenteric; Ret, retropharyngeal; Nx,
necropsy.
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tributed to stronger SIV-specific antibody responses in controller
animals and maybe also promoted stronger SIV-specific T cell
responses during chronic viremia.
To date, only three human HIV vaccine efficacy trials have
been performed, and these were conducted in adults. The RV144
trial was the only HIV vaccine trial that showed some efficacy, but
the effect was only transient. Although broadly neutralizing anti-
bodies are considered the gold standard for preventing HIV ac-
quisition, nonneutralizing antibodies were identified as correlates
of protection in RV144 (37, 38). Env-specific plasma IgG binding
antibodies, especially against the gp120 V1V2 loops, were in-
versely correlated with infection risk (39). The protective efficacy
of these IgG antibodies was not associated with their avidity (39–
43) but rather with FcR-mediated functions, such as ADCC (44).
Conversely, high levels of gp120-specific plasma IgA were posi-
tively correlated with an increased risk of HIV infection in RV144
vaccine recipients (39) expressing a nonfunctional Fc	RIIc recep-
tor (45), which has been associated with reduced IgG/NK cell-
mediated ADCC (46). Presumably, IgA interfered with IgG-me-
diated ADCC in these subjects (47).
Our pediatric p.o. M. tuberculosis-SIV/i.m. MVA-SIV vaccine
strategy was able to induce high levels of Env-specific IgG in
plasma, including V1V2-specific IgG antibodies. In animals with
lower peak viremia and reduced viremia throughout the course of
infection, gp140-specific plasma IgG antibodies had higher avidity
than those of vaccinated animals with persistently high viremia.
However, the functional capacity of these antibodies was limited.
In particular, we could not detect ADCVI in assays with neutral-
ization-resistant SIV, suggesting that ADCC antibodies were not
generated in these animals. The failure to induce these antibodies
could be due to inherent properties of the vaccine regimen and/or
related to age-dependent immune ontogeny in infants. ADCC is
thought to be mediated primarily by NK cells, although mono-
cytes may alsomediate this function (48). Regardless of which cell
type is more critical for ADCC, both monocyte and NK cell func-
tions in infants are known to be quantitatively and qualitatively
different from those of adults (reviewed in reference 49). Thus,
additional vaccine optimization may be needed to enhance the
functional capacity of innate immune cells and thereby enhance
adaptive immunity. Similarly, antigen-specific antibodies in in-
fants have been described as deficient in affinity maturation and
somatic hypermutation (50). This is consistent with the relatively
low avidity of the SIV gp140-specific plasma IgG antibodies mea-
sured before challenge in our study. SIV/HIV vaccine studies in
adult macaques have induced anti-Env plasma IgG antibodies
withmuch higher avidity (51–54). The fact that vaccinated infants
had maximal prechallenge avidity indices of 14, whereas protec-
tive vaccines in adults typically generate Env-specific IgG with
avidity indices of 30, clearly suggests that there is a need to induce
higher-avidity plasma antibodies in the infants.
Several SIV vaccine studies in adultmacaques have highlighted
the importance ofmucosal IgA in protection against SIV infection
(15, 20, 54–57), but the role of IgA in vaccine-mediated protection
against HIV acquisition remains unclear. The fact that plasma IgA
responses in the RV144 trial were positively correlated with HIV
infection risk does not negate the potential role of mucosal IgA in
the protection of HIV acquisition. In fact, monomeric plasma IgA
and polymericmucosal IgA exhibit distinct functions. In the stud-
ies described here, we observed a significant inverse relationship
between SIV Env-specific mucosal IgA antibodies and acute
viremia. Both vaccine-induced salivary and fecal SIV Env-specific
IgA activities at the time of challenge inversely correlated with
reduced acute viremia. In contrast, there was no correlation be-
tween plasma SIV Env-specific IgA and viremia. Furthermore,
while SIV Env-specific salivary and fecal IgA antibodies strongly
correlated with each other, the lack of a correlation between
plasma andmucosal IgA demonstrated thatmucosal IgA antibod-
ies were produced locally and not due to transudation.
The importance of local IgA responses was highlighted in a
recent study demonstrating that SIVDNA/MVA-vaccinated adult
macaques protected against rectal challengewith SIV showed viral
“blips,” but no persistent systemic viremia, when rechallenged
with SIV repeatedly by the rectal route roughly 6 months later.
Control of local virus replication was thought to be due to in-
creased SIV Env-specific rectal IgA observed in these animals (58).
Our finding that Env-specific fecal IgA levels further increased in
our controller animals compared to noncontrollers is reminiscent
of this finding. Due to the small volumes of saliva and stool sam-
ples, we could not evaluate potential SIV-specific mucosal IgG
responses or the functional mechanisms responsible for IgA-me-
diated control of viremia. However,mucosal IgA antibodies could
control replication of neutralization-resistant SIV in several ways.
In the intestinal lamina propria or salivary glands, nonneutraliz-
ing Env-specific polymeric IgA could mediate clearance of com-
plexed virions by binding to the polymeric immunoglobulin re-
ceptor on columnar epithelial cells and transporting virions to the
lumen (59). Resident macrophages in the GI tract typically down-
regulate Fc receptors (60), but locally synthesized anti-Env IgA
antibodies could mediate phagocytosis of SIV virions by FcR
neutrophils, monocytes, and dendritic cells recruited to infected
tissues. Finally, HIV-specific IgA has been shown to be capable of
mediating ADCC in the presence of blood monocytes (61), and it
is likely that nonneutralizing IgA andneutrophils can alsomediate
this activity (62).
Importantly, recent human studies demonstrated that HIV-
specific breast milk IgA levels could reduce the risk of HIV acqui-
sition in human infants (63). A subsequent study by the same
group showed that strong HIV Env-specific IgA responses could
be induced in lactating macaques by vaccination (64). Our results
provide evidence that protective mucosal IgA responses can also
be induced by vaccination of the infant and thereby have the po-
tential to provide long-term protection against viral acquisition
compared to transient protection by maternal antibodies. The in-
duction of potent mucosal IgA antibodies by our vaccine is a re-
markable achievement considering the age-dependent develop-
ment of mucosal IgA responses postbirth. Consistent with human
infant antibody development, plasma and salivary IgA antibodies
in infant macaques are barely detectable at birth and only slowly
increase in the first 3 months. Thus, the fact that our vaccine was
able to induce high mucosal IgA levels in some animals confirms
the feasibility of developing an effective pediatric HIV vaccine.
The current study did not allow us to distinguish between the
relative contribution of systemic IgG andmucosal IgA in the con-
trol of viremia. This is an important question to address in future
studies. An elegant study by Ruprecht et al. showed that rectal
administration of an anti-HIV V3 recombinant dimeric human
IgA2 monoclonal antibody (MAb), combined with systemic ad-
ministration of the parental IgG1 MAb, was able to completely
protect adult macaques against rectal SHIV-1157ipEL challenge,
Jensen et al.
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whereas passive immunization with only IgG1 or dIgA2 protected
only 0% and 17% of macaques, respectively (65).
Similarly, the results of this study highlight the potential im-
portance of vaccine-elicited mucosal Env-specific IgA responses
in combination with high-avidity systemic Env-specific IgG in
protection against oral SIV transmission and control of viral rep-
lication in infant macaques. By gaining a deeper understanding of
postnatal immune development, we may be able to design im-
proved vaccine strategies to enhance systemic and mucosal SIV/
HIV antibody responses.
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